Program
EDK060
A development code. Also written as “EDK060, dose A”, “EDK060, dose B” and “EDK060, dose C”.
Its studies are mostly in Charcot-Marie-Tooth Disease, led by Novartis.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 1since Aug 22, 2025 | Aug 22, 2025 | Feb 25, 2028phase 1 · NCT07140614 |
- Named in Novartis’s own pipeline as
EDK060
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 22, 2025First study: phase 1 study in Charcot-Marie-Tooth DiseaseFirst studyNCT07140614 · 28 planned · Canada
Ahead
- Feb 25, 2028Primary completion: phase 1 study in Charcot-Marie-Tooth DiseaseNCT07140614
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07140614Charcot-Marie-Tooth Disease · Canada | 1 | Recruiting | Feb 25, 2028 | 28 |
How it is read
Names in the registry
- “EDK060, dose A”, 1 entry
- “EDK060, dose B”, 1 entry
- “EDK060, dose C”, 1 entry
- “EDK060, dose D”, 1 entry
Codes read as this program: EDK060.
Conditions, from the studies’ own filings
- Charcot-Marie-Tooth Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.